newsfilter
← Latest News
Business Wire·

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

Leading Maternal-Fetal Medicine Experts to Discuss FGR Disease State, the Clinical Rationale for DM199 (Rinvecalinase Alfa) Early Safety and Trial Findings from First Cohort of Phase 2 Early-Onset FGR Trial to Be